Learn more

MUELLER-HERMELINK HANS KONRAD

Overview
  • Total Patents
    13
About

MUELLER-HERMELINK HANS KONRAD has a total of 13 patent applications. Its first patent ever was published in 2000. It filed its patents most often in Germany and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are GALAXY BIOTECH LLC, BIOSCEPTRE INT LTD and ADURO BIOTECH HOLDINGS EUROPE B V.

Patent filings in countries

World map showing MUELLER-HERMELINK HANS KONRADs patent filings in countries

Patent filings per year

Chart showing MUELLER-HERMELINK HANS KONRADs patent filings per year from 1900 to 2020

Focus industries

Top inventors

# Name Total Patents
#1 Mueller-Hermelink Hans Konrad 13
#2 Vollmers Heinz 10
#3 Hensel Frank 3
#4 Vollmers Heinz Peter 2
#5 Bargou Ralf 1
#6 Greiner Axel 1
#7 Kufer Peter 1
#8 Doerken Bernd 1

Latest patents

Publication Filing date Title
DE10353175A1 Human monoclonal antibody with fatliquoring effect
DE10352977A1 Murine anti-idiotypic antibody or rat anti-idiotype antibody of the human monoclonal SC-1 antibody
DE10311248A1 Human monoclonal antibody
DE10230516A1 New purified polypeptide (e.g. an antibody) that induces apoptosis of a neoplastic cell, useful for diagnosing or treating a neoplasm or a proliferative disorder in mammals, including humans
DE10229907A1 New purified polypeptide (e.g. an antibody) that induces apoptosis of a neoplastic cell, useful for diagnosing or treating a neoplasm or a proliferative disorder in mammals, including humans
DE10229906A1 New purified polypeptide (e.g. an antibody) that induces apoptosis of a neoplastic cell, useful for diagnosing or treating a neoplasm or a proliferative disorder in mammals, including humans
DE10210427A1 Human monoclonal antibody
DE10210425A1 New glycoprotein receptor on surface of cancer cells, useful for treatment and diagnosis of cancer and for drug screening, also new specific antibody
DE10136009A1 New glycoprotein receptor on surface of cancer cells, useful for treatment and diagnosis of cancer and for drug screening, also new specific antibody
WO0147953A2 Antibodies against plasma cells